AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26324844 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 minute walk distance (6MWD) in the French cohort
Number of subjects: 415
Study 26324844 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 minute walk distance (6MWD) in the FDA cohort
Number of subjects: 415
Study 26324844 — intervention group
Group type: COMPARATOR
Intervention: Changes in 6 minute walk distance (6MWD) during follow-up in treated patients
Number of subjects: 415
Study 27128607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 1,500 mg
Number of subjects: 60
Study 27128607 — intervention group
Group type: EXPERIMENTAL
Intervention: Mericitabine 9,000 mg
Number of subjects: 60
Study 27128607 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 60
Study 27128607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22187234 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (200 mg celecoxib and 20 mg doxycycline, both twice daily)
Number of subjects: 75
Study 22187234 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily) only
Number of subjects: 75
Study 22187234 — intervention group
Group type: COMPARATOR
Intervention: Non-therapy control
Number of subjects: 75
Study 21094838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antithymocyte globulin (ATG) therapy plus shortened standard therapy (group 1)
Number of subjects: 30
Study 21094838 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (group 2)
Number of subjects: 30
Study 21094838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ATG therapy (group 1)
Number of subjects: 30
Study 17426325 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0557 (1 mg/d)
Number of subjects: 502
Study 17426325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 15785225 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 400
Study 15785225 — intervention group
Group type: COMPARATOR
Intervention: In-person interviews
Number of subjects: 400
Study 12125299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Short‐term Dynamic Psychotherapy (ISTDP)
Number of subjects: 89
Study 12125299 — intervention group
Group type: EXPERIMENTAL
Intervention: ISTDP
Number of subjects: 89
Study 10633764 — intervention group
Group type: EXPERIMENTAL
Intervention: CapSure (Re/Stor) continence shield
Number of subjects: 0
Study 7796643 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg twice daily for three months
Number of subjects: 30
Study 7796643 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg twice daily and cyclopentylethinyl estriol (CEE3) 5 mg once a month for three months
Number of subjects: 30
Study 2127789 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b treatment (3 million units, three times weekly, subcutaneously for 36 weeks)
Number of subjects: 33
Study 2127789 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b treatment
Number of subjects: 33
Study 369644 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation (von Bahr screws)
Number of subjects: 104
Study 369644 — intervention group
Group type: COMPARATOR
Intervention: Primary prosthetic replacement (Christiansen endoprosthesis)
Number of subjects: 104
Study 30660638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma tocopherol
Number of subjects: 0
Study 30660638 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 28432265 — intervention group
Group type: EXPERIMENTAL
Intervention: Actovegin (2000 mg/d for ≤20 intravenous infusions followed by 1200 mg/d orally)
Number of subjects: 503
Study 28432265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study 25910427 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 nerve field stimulation (minimal .1 mA, subthreshold, suprathreshold)
Number of subjects: 40
Study 25910427 — intervention group
Group type: EXPERIMENTAL
Intervention: C2 nerve field stimulation
Number of subjects: 40
Study 23993734 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual chest radiograph for 3 or 4 years
Number of subjects: 154900
Study 22138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine encounter with IBD specialist remotely located
Number of subjects: 34
Study 22138934 — intervention group
Group type: COMPARATOR
Intervention: Standard encounter
Number of subjects: 34
Study 22138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine encounter
Number of subjects: 34
Study 22138934 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine sessions
Number of subjects: 34
Study 19593411 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive use of denicotinized cigarettes
Number of subjects: 0
Study 19593411 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement
Number of subjects: 0
Study 19593411 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study 16844340 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological services
Number of subjects: 517
Study 16844340 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for diagnostic purposes
Number of subjects: 517
Study 16844340 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to referral
Number of subjects: 517
Study 16844340 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care physicians
Number of subjects: 517
Study 12780901 — intervention group
Group type: EXPERIMENTAL
Intervention: SCL/RBL (simultaneous sclerotherapy and rubber band ligation)
Number of subjects: 255
Study 12780901 — intervention group
Group type: EXPERIMENTAL
Intervention: SCL (sclerotherapy)
Number of subjects: 255
Study 12780901 — intervention group
Group type: COMPARATOR
Intervention: RBL (rubber band ligation)
Number of subjects: 255
Study 11028571 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing (20 μg/day) intrauterine system (LNG-20)
Number of subjects: 5
Study 11028571 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine devices ≤ 250 mm3
Number of subjects: 5
Study 11028571 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine devices > 250 mm3
Number of subjects: 5
Study 11028571 — intervention group
Group type: COMPARATOR
Intervention: Norplant-2
Number of subjects: 5
Study 9198052 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal administration of hepatitis B recombinant DNA yeast vaccine (80 micrograms)
Number of subjects: 50
Study 9198052 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular administration of hepatitis B recombinant DNA yeast vaccine (80 micrograms)
Number of subjects: 50
Study 9198052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of intradermal schedule
Number of subjects: 50
Study 1376843 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 1.25 mg
Number of subjects: 27
Study 1376843 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg
Number of subjects: 27
Study 1376843 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg
Number of subjects: 27
Study 1376843 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (all groups)
Number of subjects: 27
Study 3884404 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 10
Study 3884404 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 10
Study 3884404 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CIT and CSII
Number of subjects: 10
Study 30709385 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-day Lenten-themed physical activity intervention (Savior's Sandals)
Number of subjects: 187
Study 30709385 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 187
Study 29177475 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI plus ablation of low-voltage areas (LVAs)
Number of subjects: 124
Study 29177475 — intervention group
Group type: COMPARATOR
Intervention: PVI with or without linear ablation (control group)
Number of subjects: 124
Study 26457895 — intervention group
Group type: EXPERIMENTAL
Intervention: Early substitution group (ROTEM FIBTEM trigger <13 mm)
Number of subjects: 0
Study 26457895 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (ROTEM FIBTEM trigger <8 mm)
Number of subjects: 0
Study 25498770 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22310510 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic resistance exercise (HR)
Number of subjects: 8
Study 22310510 — intervention group
Group type: COMPARATOR
Intervention: Normoxic resistance exercise (NR)
Number of subjects: 8
Study 19614793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intervention to reduce hemoglobin A(1c)
Number of subjects: 58
Study 17889694 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-cooled
Number of subjects: 37
Study 17889694 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-cooled
Number of subjects: 37
Study 17889694 — intervention group
Group type: EXPERIMENTAL
Intervention: No coolant
Number of subjects: 37
Study 15191590 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD)
Number of subjects: 42
Study 15191590 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 42
Study 15191590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EMD and GTR
Number of subjects: 42
Study 15191590 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 42
Study 11755800 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP) with intense home visitation by public health nurses (PHNs)
Number of subjects: 102
Study 11755800 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP)
Number of subjects: 102
Study 11755800 — intervention group
Group type: COMPARATOR
Intervention: Traditional Public Health Nursing care (TPHN)
Number of subjects: 102
Study 11755800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EIP and TPHN
Number of subjects: 102
Study 9848540 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 250 mg plus Amoxicillin 500 mg, 3 times/day for a week
Number of subjects: 46
Study 9848540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9848540 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole plus Amoxicillin (M+A)
Number of subjects: 46
Study 8024227 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium nadroparin (fixed dose: daily subcutaneous injection of 0.6 ml, i.e. 6150 anti‐Xa IU, n = 38)
Number of subjects: 117
Study 8024227 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium nadroparin (weight-adjusted dose: 31.5 anti‐Xa IU/kg, n = 40)
Number of subjects: 117
Study 8024227 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg as a single daily dose, n = 39)
Number of subjects: 117
Study 2689915 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 44
Study 2689915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 1095134 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofluorophosphate (25 mg fluoride per day)
Number of subjects: 460
Study 1095134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride treatment)
Number of subjects: 460
Study 31153674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotype-adjusted diet
Number of subjects: 209
Study 31153674 — intervention group
Group type: COMPARATOR
Intervention: Typical hypocaloric dietary treatment
Number of subjects: 209
Study 31814707 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7594 (1600 µg)
Number of subjects: 9
Study 31814707 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7594
Number of subjects: 9
Study 31814707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 28407543 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cannabis (6.9% THC, ∼54mg)
Number of subjects: 0
Study 28407543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis (6.9% THC, ∼54mg)
Number of subjects: 0
Study 28407543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis (6.9% THC, ∼54mg)
Number of subjects: 0
Study 28407543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.001% Δ9‐tetrahydrocannabinol [THC])
Number of subjects: 0
Study 24486815 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI while awake with age-adjusted routines (booklet, story book, model of MRI scanner, DVD film)
Number of subjects: 69
Study 24486815 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI while awake with age-adjusted routines
Number of subjects: 69
Study 24486815 — intervention group
Group type: COMPARATOR
Intervention: MRI under anesthesia
Number of subjects: 69
Study 24486815 — intervention group
Group type: COMPARATOR
Intervention: MRI while awake
Number of subjects: 69
Study 23247700 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exercise (12-week supervised exercise program)
Number of subjects: 22
Study 21689343 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent blue V dye injection
Number of subjects: 68
Study 21689343 — intervention group
Group type: COMPARATOR
Intervention: No patent blue V dye injection
Number of subjects: 68
Study 21689343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after application of Carnoy's solution
Number of subjects: 68
Study 17676535 — intervention group
Group type: EXPERIMENTAL
Intervention: Paging system intervention for 7 weeks
Number of subjects: 4
Study 17676535 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurement (no pager)
Number of subjects: 4
Study 17676535 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention monitoring (5 weeks after returning pagers)
Number of subjects: 4
Study 16174897 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) 5 g infused during 1 hour, then 1 g/hour for 23 hours
Number of subjects: 14
Study 16174897 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 14
Study 16174897 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 14
Study 11928795 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb-sparing surgery with adjuvant radiation
Number of subjects: 0
Study 11928795 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (external beam and brachytherapy)
Number of subjects: 0
Study 11928795 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 11928795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (not specified)
Number of subjects: 0
Study 11928795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin-based chemotherapy
Number of subjects: 0
Study 9788526 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0, 1, 2 mg)
Number of subjects: 48
Study 9788526 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (0, 12.5, 25 mg)
Number of subjects: 48
Study 9788526 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (0, 60, 120 mg)
Number of subjects: 48
Study 9788526 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (0, 3.58% THC)
Number of subjects: 48
Study 9788526 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Recognition Examiners (DREs) decisions
Number of subjects: 48
Study 9788526 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug class decisions by DREs
Number of subjects: 48
Study 7697134 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA (10 mg/kg, oral)
Number of subjects: 34
Study 7697134 — intervention group
Group type: COMPARATOR
Intervention: EDTA (1 g, intravenous)
Number of subjects: 34
Study 7697134 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA after EDTA
Number of subjects: 34
Study 2487304 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nitrofurantoin (100 mg t.i.d.) for five days
Number of subjects: 103
Study 2487304 — intervention group
Group type: COMPARATOR
Intervention: Oral ampicillin (500 mg t.i.d.) for five days
Number of subjects: 103
Study 20124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic (5-min period)
Number of subjects: 0
Study 20124 — intervention group
Group type: COMPARATOR
Intervention: Beta1-adrenoceptor selective blocker (metoprolol)
Number of subjects: 0
Study 20124 — intervention group
Group type: COMPARATOR
Intervention: Non-selective blockers (e.g., propranolol)
Number of subjects: 0
Study 31308592 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Number of subjects: 24
Study 31308592 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Number of subjects: 24
Study 31308592 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary BPB technique with 0.2 mL/kg BW of bupivacaine 0.5%
Number of subjects: 24
Study 31308592 — intervention group
Group type: COMPARATOR
Intervention: Other surgical procedures (control group)
Number of subjects: 24
Study 29275577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil maintenance regimen (group SR, n=50)
Number of subjects: 100
Study 29275577 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane maintenance regimen (group S, n=50)
Number of subjects: 100
Study 25173085 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with dose constraints on the brachial plexus (BP) (maximum dose limit of ≤66 Gy)
Number of subjects: 30
Study 25173085 — intervention group
Group type: COMPARATOR
Intervention: IMRT without restrictions for the BP
Number of subjects: 30
Study 25173085 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with dose constraints on the BP
Number of subjects: 30
Study 23885792 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (20-40 mg once daily)
Number of subjects: 548
Study 23885792 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (8-12 mg once daily)
Number of subjects: 548
Study 21505785 — intervention group
Group type: COMPARATOR
Intervention: GPIbα C mutated allele in smokers
Number of subjects: 114
Study 21505785 — intervention group
Group type: COMPARATOR
Intervention: PAR‐1A/T SNP and other SNPs tested
Number of subjects: 114
Study 21505785 — intervention group
Group type: COMPARATOR
Intervention: GPIb‐α (5C/T) prevalence in smokers
Number of subjects: 114
Study 18248979 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus BCNU and DBD (n=94)
Number of subjects: 193
Study 18248979 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (n=99)
Number of subjects: 193
Study 16835585 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 60
Study 16835585 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 60
Study 15356496 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated elastomers
Number of subjects: 30
Study 15356496 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoridated elastomers
Number of subjects: 30
Study 11782868 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cow milk protein-based formula with added cholesterol (RF+cholesterol) 3.44 mmol cholesterol/L (133 mg cholesterol/L)
Number of subjects: 81
Study 11782868 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cow milk protein-based formula (RF)
Number of subjects: 81
Study 11782868 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed (BF)
Number of subjects: 81
Study 11782868 — intervention group
Group type: COMPARATOR
Intervention: Regular cow milk protein-based formula with added cholesterol (RF+cholesterol)
Number of subjects: 81
Study 9667247 — intervention group
Group type: EXPERIMENTAL
Intervention: CHVP + IFNalpha
Number of subjects: 268
Study 9667247 — intervention group
Group type: COMPARATOR
Intervention: CHVP alone
Number of subjects: 268
Study 7700540 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 0
Study 7700540 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 2748223 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (salbutamol)
Number of subjects: 2
Study 2748223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 341407 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (40 microgram)
Number of subjects: 19
Study 341407 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4 mg)
Number of subjects: 19
Study 341407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31471767 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 31471767 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education program (DSE)
Number of subjects: 0
Study 29292066 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of 5.0 ppm F milk once per day
Number of subjects: 25
Study 29292066 — intervention group
Group type: COMPARATOR
Intervention: 100 ml of 5.0 ppm F twice per day
Number of subjects: 25
Study 29292066 — intervention group
Group type: COMPARATOR
Intervention: 200 ml of 5.0 ppm F once every other day
Number of subjects: 25
Study 29292066 — intervention group
Group type: COMPARATOR
Intervention: All groups (once per day, twice per day, once every other day)
Number of subjects: 25
Study 26864002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal anaesthesia with 40 mg intrathecal hyperbaric prilocaine
Number of subjects: 100
Study 26864002 — intervention group
Group type: COMPARATOR
Intervention: Peripheral nerve blockade with 25 ml mepivacaine 2%
Number of subjects: 100
Study 25478791 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week Internet intervention providing tailored physical activity counseling
Number of subjects: 120
Study 25478791 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up by school nurses (Control)
Number of subjects: 120
Study 22506889 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared reading program with print references (2 or 4 times per week for 30 weeks)
Number of subjects: 550
Study 22506889 — intervention group
Group type: COMPARATOR
Intervention: Typical book reading style (comparison classrooms)
Number of subjects: 550
Study 20169950 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg x kg(‐1)
Number of subjects: 30